Staphefekt – intervening early in the Colonisation Infection Continuum with endolysins
With Staphefekt, the first targeted therapy against S. aureus is available for long-term daily maintenance therapy, aimed at decreasing the burden of skin colonisation and preventing progression to inflammation and infection.